icrf 193 has been researched along with razoxane in 18 studies
| Studies (icrf 193) | Trials (icrf 193) | Recent Studies (post-2010) (icrf 193) | Studies (razoxane) | Trials (razoxane) | Recent Studies (post-2010) (razoxane) |
|---|---|---|---|---|---|
| 155 | 0 | 30 | 824 | 115 | 56 |
| Protein | Taxonomy | icrf 193 (IC50) | razoxane (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (44.44) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Andoh, T; Ikegami, Y; Ishida, R; Tanabe, K | 1 |
| Andoh, T; Ishida, R; Miki, T; Narita, T; Sato, M; Tanabe, K; Utsumi, KR; Yui, R | 1 |
| Andoh, T; Hamatake, M; Ishida, R; Nitiss, JL; Wang, JC; Wasserman, RA | 1 |
| Furue, H | 1 |
| Chadwick, DP; Clark, JR; Ferrans, VJ; Hasinoff, BB; Herman, EH; Zhang, J | 1 |
| Allan, WP; Creighton, AM; Hasinoff, BB; Kozlowska, H; Thampatty, P; Yalowich, JC | 1 |
| Creighton, AM; Holm, B; Jensen, LH; Jensen, PB; Kenwrick, S; Nitiss, JL; Oliveri, RS; Sehested, M; Wessel, I | 1 |
| Clerc, X; Creighton, AM; Hill, BT; van Hille, B | 1 |
| Dong, J; Hu, T; Jensen, LH; Jensen, PB; Nitiss, JL; Nitiss, KC; Osheroff, N; Rose, A; Sehested, M; Zhou, J | 1 |
| Jensen, LH; Jensen, PB; Møller, M; Nitiss, JL; Sehested, M; Wessel, I | 1 |
| Barret, JM; Etiévant, C; Hill, BT; Kruczynski, A; van Hille, B | 1 |
| Jensen, LH; Jensen, PB; Nitiss, JL; Renodon-Cornière, A; Sehested, M | 1 |
| Higashihara, M; Honma, Y; Niitsu, N | 1 |
| Jensen, LH; Jensen, PB; Nitiss, JL; Renodon-Cornière, A; Sehested, M; Søkilde, B; Sørensen, TK | 1 |
| Grauslund, M; Jensen, LH; Jensen, PB; Sehested, M; Sorensen, TK | 1 |
| Grauslund, M; Hasinoff, BB; Jensen, LH; Liang, H; Sehested, M; Shoemaker, R | 1 |
| Füchtbauer, A; Füchtbauer, EM; Grauslund, M; Hjorth, PH; Hofland, KF; Jensen, LH; Jensen, PB; Sehested, M; Thougaard, AV | 1 |
| Bavlovič Piskáčková, H; Chládek, J; Jansová, H; Jirkovská, A; Karabanovich, G; Kollárová-Brázdová, P; Kubeš, J; Lenčová-Popelová, O; Melnikova, I; Roh, J; Šimůnek, T; Štěrba, M; Štěrbová-Kovaříková, P; Váňová, N | 1 |
1 review(s) available for icrf 193 and razoxane
| Article | Year |
|---|---|
[Topoisomerase inhibitors developing in Japan].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzopyrans; Camptothecin; Diketopiperazines; Glycosides; Humans; Irinotecan; Neoplasms; Phenazines; Piperazines; Razoxane; Topotecan | 1993 |
17 other study(ies) available for icrf 193 and razoxane
| Article | Year |
|---|---|
Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Topics: Antineoplastic Agents; Diketopiperazines; DNA; Piperazines; Razoxane; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1991 |
Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
Topics: Cell Cycle; Cell Division; Cell Nucleus; Diketopiperazines; DNA Damage; Humans; Mitosis; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Spindle Apparatus; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1991 |
DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
Topics: Amsacrine; Antineoplastic Agents; Diketopiperazines; DNA Topoisomerases, Type II; Drug Hypersensitivity; Drug Resistance; Piperazines; Razoxane; Saccharomyces cerevisiae; Topoisomerase II Inhibitors | 1995 |
Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Topics: Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Chelating Agents; Diketopiperazines; DNA Topoisomerases, Type II; Doxorubicin; Ethylenediamines; Glycine; Heart; Hydrolysis; Iron; Male; Myocardium; Piperazines; Rats; Rats, Inbred SHR; Razoxane | 1997 |
Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site.
Topics: Animals; Antineoplastic Agents; CHO Cells; Cricetinae; Diketopiperazines; DNA; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Indoles; Isoindoles; Piperazines; Razoxane; Topoisomerase II Inhibitors | 1997 |
Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Topics: Amino Acid Sequence; Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Base Sequence; Blotting, Western; CHO Cells; Cricetinae; Diketopiperazines; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Isoenzymes; Molecular Sequence Data; Mutation; Piperazines; Razoxane; Saccharomyces cerevisiae; Topoisomerase II Inhibitors | 1998 |
Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds.
Topics: Antineoplastic Agents; Diketopiperazines; DNA Damage; DNA Topoisomerases, Type I; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fungal Proteins; Humans; Piperazines; Rad52 DNA Repair and Recombination Protein; Razoxane; Reproducibility of Results; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1999 |
A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines.
Topics: Alleles; Antineoplastic Agents; Cell Cycle; Diketopiperazines; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Enzyme Inhibitors; Genes, Dominant; Humans; Microbial Sensitivity Tests; Mutagenesis; Piperazines; Protein Conformation; Razoxane; Saccharomyces cerevisiae; Time Factors; Topoisomerase II Inhibitors; Ultracentrifugation | 2000 |
N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance.
Topics: Adenosine Triphosphate; Amsacrine; Antigens, Neoplasm; Diketopiperazines; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Mutagenesis; Nucleic Acid Synthesis Inhibitors; Piperazines; Razoxane; Topoisomerase II Inhibitors | 2000 |
Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Diketopiperazines; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Female; Humans; Leukemia P388; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Naphthalenes; Neoplasm Transplantation; Piperazines; Pyrans; Razoxane; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2000 |
Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance.
Topics: Adenylyl Imidodiphosphate; Antigens, Neoplasm; Binding Sites; Diketopiperazines; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Enzyme Stability; Humans; Isoenzymes; Mutagenesis, Site-Directed; Piperazines; Plasmids; Protein Binding; Razoxane; Saccharomyces cerevisiae; Substrate Specificity; Surface Plasmon Resonance; Topoisomerase II Inhibitors; Tyrosine | 2002 |
The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukem
Topics: Antineoplastic Agents; Catalysis; Cell Cycle; Cell Differentiation; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytarabine; Daunorubicin; Deoxycytidine; Diketopiperazines; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Granulocytes; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Razoxane; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Messenger; RNA, Neoplasm; Topoisomerase II Inhibitors; Tretinoin; Tumor Cells, Cultured; U937 Cells | 2002 |
Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha.
Topics: Adenosine Triphosphate; Antigens, Neoplasm; Catalysis; Diketopiperazines; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Genetic Complementation Test; Humans; Indoles; Isoindoles; Mutagenesis, Site-Directed; Piperazines; Razoxane; Topoisomerase II Inhibitors; Yeasts | 2003 |
Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.
Topics: Adenosine Triphosphatases; Amino Acid Substitution; Antigens, Neoplasm; Diketopiperazines; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance; Humans; Kinetics; Piperazines; Razoxane; Topoisomerase II Inhibitors; Vanadates | 2005 |
A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Topics: Adenosine Triphosphatases; Antigens, Neoplasm; Catalysis; Cell Line; Diketopiperazines; DNA; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; HCT116 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Models, Molecular; Mutant Proteins; Piperazines; Purines; Quantitative Structure-Activity Relationship; Razoxane; Static Electricity; Topoisomerase II Inhibitors | 2006 |
A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo.
Topics: Animals; Antigens, Neoplasm; Base Sequence; Blotting, Western; Diketopiperazines; DNA Primers; DNA Topoisomerases, Type II; DNA-Binding Proteins; Female; Mice; Mice, Transgenic; Mutagenesis, Site-Directed; Piperazines; Poly-ADP-Ribose Binding Proteins; Razoxane | 2007 |
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
Topics: Animals; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Diketopiperazines; DNA Topoisomerases, Type II; Male; Myocytes, Cardiac; Piperazine; Prodrugs; Rabbits; Razoxane; Topoisomerase II Inhibitors; Water | 2021 |